The estimated Net Worth of Mark A Wan is at least $12.5 Million dollars as of 7 March 2014. Mr. Wan owns over 1,000,000 units of Acelrx Pharmaceuticals Inc stock worth over $108,492 and over the last 12 years he sold ACRX stock worth over $12,350,000. In addition, he makes $69,754 as Independent Director at Acelrx Pharmaceuticals Inc.
Mark has made over 1 trades of the Acelrx Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 1,000,000 units of ACRX stock worth $12,350,000 on 7 March 2014.
The largest trade he's ever made was selling 1,000,000 units of Acelrx Pharmaceuticals Inc stock on 7 March 2014 worth over $12,350,000. On average, Mark trades about 76,923 units every 0 days since 2012. As of 7 March 2014 he still owns at least 126,153 units of Acelrx Pharmaceuticals Inc stock.
You can see the complete history of Mr. Wan stock trades at the bottom of the page.
Mark A. Wan serves as Independent Director of the Company. Mr. Wan is a founding managing director of Causeway Media Partners, a private investment firm, which was founded in 2013. He is also a founding general partner of Three Arch Partners, a venture capital firm. Prior to co-founding Three Arch Partners in 1993, Mr. Wan was a general partner at Brentwood Associates, a private equity firm from 1987 until 1993. Mr. Wan currently serves on the board of directors of QT Vascular Ltd., a public Singapore-based medical device company. In addition, Mr. Wan currently serves on the board of directors for a number of private firms, including ETN Media, Inc., FloSports, Inc., VenueNext, Inc., QuintEvents, LLC, Stio, Freeletics, Momentous, CareConnect and SanoV Pte Ltd, which is based in Singapore. He is chair of the board of directors for Jackson Hole Community School, an independent private school, and also serves on the board of directors for Resource Legacy Fund and the Monterey Bay Aquarium, both of which are non-profit institutions. From 1999 until its acquisition by athenahealth, Inc., in March 2013, Mr. Wan served on the board of directors of Epocrates, Inc., a company focused on providing mobile drug reference tools. Mr. Wan holds a B.S. in Engineering from Yale University and an M.B.A. from the Stanford Graduate School of Business. Mr. Wan’s financial experience and extensive knowledge of our company provides him with the qualifications and skills to serve as a director.
As the Independent Director of Acelrx Pharmaceuticals Inc, the total compensation of Mark Wan at Acelrx Pharmaceuticals Inc is $69,754. There are 11 executives at Acelrx Pharmaceuticals Inc getting paid more, with Vincent Angotti having the highest compensation of $2,125,050.
Mark Wan is 54, he's been the Independent Director of Acelrx Pharmaceuticals Inc since 2006. There are 10 older and 4 younger executives at Acelrx Pharmaceuticals Inc. The oldest executive at Acelrx Pharmaceuticals Inc is Lawrence G. Hamel, 69, who is the Consultant.
Mark's mailing address filed with the SEC is 19 S B St #14, San Mateo, CA 94401, USA.
Over the last 14 years, insiders at Acelrx Pharmaceuticals Inc have traded over $25,363,406 worth of Acelrx Pharmaceuticals Inc stock and bought 5,245,025 units worth $26,783,172 . The most active insiders traders include Advisors Llcperceptive Life..., Advisors Llcedelman Josephp... und Mark Ajaeger Wilfred Ethree.... On average, Acelrx Pharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of $109,939. The most recent stock trade was executed by Vincent J. Angotti on 13 December 2023, trading 10,000 units of ACRX stock currently worth $7,300.
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Acelrx Pharmaceuticals Inc executives and other stock owners filed with the SEC include: